Ancillary Studies to the AD Neuroimaging Initiative (R03) | Apply Online

Frequently Asked Questions (FAQs): Ancillary Studies to the AD Neuroimaging Initiative (R03) (PA-06-240)

What is the purpose of the NIH funding opportunity PA-06-240?

This NIH opportunity, titled "Ancillary Studies to the AD Neuroimaging Initiative (R03)" (PA-06-240), was designed to support small, focused research projects that add value to the Alzheimer's Disease Neuroimaging Initiative (ADNI). The intent is to fund targeted "add-on" studies that either (1) use ADNI data and biospecimens in new ways or (2) extend ADNI methods into complementary settings, with the broader goal of improving how Alzheimer’s disease progression is detected, tracked, and understood.

What is ADNI, and who does it study?

ADNI is a large, multi-site, longitudinal study that follows participants over time across three groups: normal cognitive aging, mild cognitive impairment (MCI), and early Alzheimer's disease (AD). The study collects multiple types of measures repeatedly over time, enabling research on change and progression.

What kinds of projects were considered "ancillary studies" under this FOA?

The FOA emphasizes small, discrete projects that complement ADNI rather than duplicate the core effort. Examples described in the announcement include biomarker discovery/validation using ADNI biospecimens, new analytical and image-processing methods for ADNI data, parallel studies that apply subsets of ADNI protocol measures in a separate cohort, and autopsy studies that link clinical and biomarker findings to post-mortem neuropathology.

Does the FOA focus on biomarkers, and if so, what types?

Yes. A central theme is biomarker discovery and validation tied to real clinical outcomes. The FOA specifically highlights genomic, proteomic, and metabolomic markers, with an emphasis on connecting biological signals to ADNI clinical, neuropsychological, and neuroimaging measures.

What biospecimens are available through ADNI for these kinds of ancillary analyses?

ADNI is collecting and storing serial biological samples, including blood, cerebrospinal fluid (CSF), and urine, from participants across the study groups. These serial samples are intended for analyses of candidate biomarkers that could reflect disease onset or progression.

How does the FOA expect biomarker results to be validated or interpreted?

Projects are expected to leverage ADNI's integrated dataset. The FOA stresses linking biomarker findings to ADNI clinical outcomes, neuropsychological performance, diagnoses, and neuroimaging changes over time. In practical terms, biomarker signals are expected to be tested against meaningful longitudinal trajectories and outcomes rather than being reported in isolation.

Are genetic or cell-based resources mentioned in the announcement?

Yes. The announcement notes that immortalized cell lines will be established. This signals an interest in enabling downstream mechanistic or genetic work that can be tied back to well-characterized ADNI participants and their longitudinal clinical and imaging data.

Are computational, statistical, or image-processing methods eligible topics?

Yes. The FOA explicitly welcomes methodological and computational contributions, including new approaches for analyzing the ADNI dataset, image processing techniques, and statistical analysis methods. The goal is to make existing ADNI data more powerful, interpretable, and clinically relevant.

What kinds of methodological improvements does the FOA highlight?

The FOA mentions projects aimed at improving extraction of imaging features, better quantifying longitudinal change, strengthening prediction of conversion from MCI to AD, reducing measurement noise, and building more informative models that combine imaging with cognitive and fluid biomarker data.

Does an ancillary study have to be conducted within ADNI itself?

No. The announcement allows studies that run in parallel to ADNI rather than directly operating within it. One option described is to develop a separate neuroimaging study using a different sample while using a subset of ADNI protocol measures, typically to assess generalizability, compare populations, or evaluate performance across settings or scanners.

Are autopsy studies allowed under this FOA?

Yes. The FOA mentions autopsy studies as an allowable area. This reflects the value of linking ante-mortem biomarkers and imaging trajectories to post-mortem neuropathology, which can provide ground-truth validation for proposed biomarkers and imaging signals.

What grant mechanism is used for PA-06-240?

This is an NIH discretionary grant using the R03 mechanism. The R03 mechanism is commonly used for small research projects, pilot studies, and discrete, well-defined aims.

What is the maximum award amount listed in the opportunity?

The opportunity lists an award ceiling of $50,000.

Is cost sharing or matching required?

No. The FOA states that there is no cost sharing or matching requirement.

When were applications due?

The FOA describes the application due dates as multiple receipt dates, with details available in the full announcement.

Is this funding opportunity currently active?

No. The FOA was originally posted on March 17, 2006, and it is archived with an archive date of June 1, 2009. That means it is not a currently active solicitation today, though it can still be useful as a reference for the types of ancillary projects NIH sought around ADNI at that time.

Who is eligible to apply?

Eligibility is broad. It includes public and private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), and many types of government entities such as state, county, city or township governments, special district governments, tribal governments and tribal organizations, and public housing authorities/Indian housing authorities. The eligibility section also states that foreign institutions are eligible, and eligible agencies of the Federal Government are eligible as well.

Are foreign institutions allowed to apply?

Yes. The eligibility section explicitly states that foreign institutions are eligible to apply.

Which federal agency is responsible for this opportunity?

The responsible agency is the National Institutes of Health (NIH).

Which CFDA program areas are associated with this FOA?

The activity categories are tied to CFDA numbers 93.286 (Discovery and Applied Research for Technological Innovations to Improve Human Health) and 93.866 (Aging Research).

What would have made an application strong or competitive under this FOA?

Based on the announcement, a strong application would have clearly explained how the proposed ancillary work uniquely complements ADNI, why it cannot be accomplished by the core ADNI effort alone, and how it will produce interpretable results connected back to disease progression. Examples of competitive ideas mentioned or implied include: a biomarker with a strong rationale and feasible measurement plan; a novel analytic method that improves inference or prediction using ADNI data; a parallel study that meaningfully extends ADNI methods into a new cohort; or autopsy-linked validation that strengthens confidence in imaging or fluid biomarker signals.

Where can applicants find the official announcement and requirements?

The FOA points to the NIH Guide page for full details and official requirements: http://grants.nih.gov/grants/guide/pa-files/PA-06-240.html